Biomea Fusion (BMEA) Current Assets (2020 - 2026)
Biomea Fusion (BMEA) posted Current Assets of $46.3 million for Q1 2026, down 20.21% sequentially from $58.0 million in Q4 2025, and up 3.65% YoY from $44.7 million in Q1 2025.
Biomea Fusion (BMEA) Current Assets (2020 - 2026) Analysis & Trends
Biomea Fusion has reported Current Assets for 7 years, with the latest figure at $46.3 million in Q1 2026.
- Quarterly Current Assets rose 3.65% year-over-year to $46.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $46.3 million (up 3.65% YoY) and the FY2025 annual result came in at $58.0 million, down 15.05% from the prior year.
- Current Assets slipped to $46.3 million in Q1 2026 per BMEA's latest filing, from $58.0 million in the prior quarter.
- Over five years, Current Assets peaked at $225.9 million in Q2 2023 and troughed at $44.7 million in Q1 2025.
- A 5-year average of $115.5 million and a median of $116.3 million in 2024 frame the typical range for Current Assets.
- The sharpest annual moves came in 2022 and 2025: Current Assets surged 251.46% in 2022, then sank 69.72% in 2025.
- Over 5 years, Current Assets stood at $117.8 million in 2022, then jumped by 52.08% to $179.2 million in 2023, then tumbled by 61.86% to $68.3 million in 2024, then dropped by 15.05% to $58.0 million in 2025, then slipped by 20.21% to $46.3 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $46.3 million, $58.0 million, and $49.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.76 Bn |
| 10 | Biomea Fusion | 97.69 Mn | 97.69 Mn | - | 36.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 36.43 Mn |
| Mar 31, 2026 | 46.32 Mn |
| Dec 31, 2025 | 58.05 Mn |
| Sep 30, 2025 | 49.44 Mn |
| Jun 30, 2025 | 64.66 Mn |
| Mar 31, 2025 | 44.69 Mn |
| Dec 31, 2024 | 68.33 Mn |
| Sep 30, 2024 | 93.60 Mn |
| Jun 30, 2024 | 116.29 Mn |
| Mar 31, 2024 | 147.57 Mn |
| Dec 31, 2023 | 179.18 Mn |
| Sep 30, 2023 | 202.50 Mn |
| Jun 30, 2023 | 225.94 Mn |
| Mar 31, 2023 | 88.93 Mn |
| Dec 31, 2022 | 117.82 Mn |
| Sep 30, 2022 | 138.86 Mn |
| Jun 30, 2022 | 154.14 Mn |
| Mar 31, 2022 | 167.02 Mn |
| Dec 31, 2021 | 176.56 Mn |
| Sep 30, 2021 | 191.10 Mn |